SecBot SecBot
8-K ·Filed May 7, 2026

CRVS

Corvus Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed6mo ago SEC0001171843-26-003154
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Focus shifts to SID meeting on May 14 for biomarker data that could support soquelitinib's differentiated profile. No near-term revenue catalysts. Monitor Phase 2 AD enrollment updates.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$15.55
T+0 close · May 7, 2026 · via day close
Latest settled
−10.48%
T+60 · $13.92
Vs SPY
−15.32%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $15.55entry
  2. T+1 · 6mo ago +1.67%α +1.44% · $15.81
  3. T+5 · 6mo ago −12.19%α −13.65% · $13.66
  4. T+20 · 5mo ago −28.49%α −28.51% · $11.12
  5. T+60 · 3mo ago −10.48%α −15.32% · $13.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Corvus Pharmaceuticals reported Q1 2026 net loss of $13.7M ($0.15/share), slightly missing consensus of $0.14 loss. The miss is marginal and overshadowed by positive pipeline progress: soquelitinib Phase 2 AD trial initiation, ongoing Phase 3 PTCL enrollment, and upcoming SID data presentation on May 14.

Key Financial Metrics

EPS
−$0.15
est −$0.14 · -7.1%
Rating
miss

Key Facts

  • Net loss per share $0.15 vs consensus $0.14 (7.1% miss)
  • Cash, cash equivalents and marketable securities $236.7M as of March 31, 2026
  • Phase 2 atopic dermatitis trial initiated in Q1 2026
  • Registrational Phase 3 PTCL trial enrollment continues
  • New soquelitinib data to be presented at SID Annual Meeting May 13-16, 2026

Financial Impact

EPS $0.01 miss on $0.14 consensus is marginal; no revenue impact for pre-revenue biotech

epscash

Risk Factors

  • Clinical trial failure or delays
  • Dilution risk from future financing (cash runway to Q2 2028)
  • No approved products or revenue

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-003154
Document: f8k_050726.htm0001171843-26-003154
Document: 0001171843-26-003154-index-headers.html0001171843-26-003154
Document: 0001171843-26-003154-index.html0001171843-26-003154
Document: 0001171843-26-003154.txt0001171843-26-003154
8-K Data (Synthetic)0001171843-26-003154

Track record

15 reports on CRVS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
  4. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
  5. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
  6. Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
  7. Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
  8. Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
  10. May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026